Literature DB >> 27078630

No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing: Show Me the Data.

Howard Jack West1.   

Abstract

Mesh：

Year:  2016        PMID： 27078630     DOI： 10.1001/jamaoncol.2016.0075

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  14 in total

1.  Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.

Authors:  Julia R Trosman; Christine B Weldon; Michael P Douglas; Patricia A Deverka; John B Watkins; Kathryn A Phillips
Journal:  Value Health       Date:  2017-01       Impact factor: 5.725

2.  Real-World Data on Liquid Biopsy Use in Non-Small Cell Lung Cancer in the Community Setting.

Authors:  Kathrin Dvir; Gliceida M Galarza-Fortuna; Joel M Haines; Paulina Gines; Ana L Ruiz; Estelamari Rodriguez
Journal:  J Immunother Precis Oncol       Date:  2021-02-03

Review 3.  Clinical potential of mass spectrometry-based proteogenomics.

Authors:  Bing Zhang; Jeffrey R Whiteaker; Andrew N Hoofnagle; Geoffrey S Baird; Karin D Rodland; Amanda G Paulovich
Journal:  Nat Rev Clin Oncol       Date:  2019-04       Impact factor: 66.675

4.  Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program.

Authors:  Evangelia Katsoulakis; Jill E Duffy; Bradley Hintze; Neil L Spector; Michael J Kelley
Journal:  JCO Precis Oncol       Date:  2020-03-24

5.  Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.

Authors:  Carolyn J Presley; Daiwei Tang; Pamela R Soulos; Anne C Chiang; Janina A Longtine; Kerin B Adelson; Roy S Herbst; Weiwei Zhu; Nathan C Nussbaum; Rachael A Sorg; Vineeta Agarwala; Amy P Abernethy; Cary P Gross
Journal:  JAMA       Date:  2018-08-07       Impact factor: 56.272

6.  Functional precision cancer medicine-moving beyond pure genomics.

Authors:  Anthony Letai
Journal:  Nat Med       Date:  2017-09-08       Impact factor: 53.440

7.  Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?

Authors:  Kathryn A Phillips
Journal:  JAMA       Date:  2018-06-19       Impact factor: 56.272

8.  Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.

Authors:  John Marquart; Emerson Y Chen; Vinay Prasad
Journal:  JAMA Oncol       Date:  2018-08-01       Impact factor: 31.777

9.  Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing.

Authors:  Nirali M Patel; Vanessa V Michelini; Jeff M Snell; Saianand Balu; Alan P Hoyle; Joel S Parker; Michele C Hayward; David A Eberhard; Ashley H Salazar; Patrick McNeillie; Jia Xu; Claudia S Huettner; Takahiko Koyama; Filippo Utro; Kahn Rhrissorrakrai; Raquel Norel; Erhan Bilal; Ajay Royyuru; Laxmi Parida; H Shelton Earp; Juneko E Grilley-Olson; D Neil Hayes; Stephen J Harvey; Norman E Sharpless; William Y Kim
Journal:  Oncologist       Date:  2017-11-20

Review 10.  The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology.

Authors:  Margaret Morash; Hannah Mitchell; Himisha Beltran; Olivier Elemento; Jyotishman Pathak
Journal:  J Pers Med       Date:  2018-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.